Taking a medical wearable to the UK
A listed neurotechnology company had UK regulatory registration for its wearable muscle-sensing device and early pilots, but no UK channel, pricing or clinic-facing proposition.
What we did and the return
What we did. Alongside XV Capital Advisory, we produced an independent UK market report: where affluence, self-pay demand and premium physiotherapy overlap, the priority locations, a clinic-led route to market and a founding-partner programme, with a phased entry plan and pilot measures.
The return. An evidence-led route into the UK that lets the company commit capital one phase at a time.